View Mobile Site

Modified stem cells from muscular dystrophy patients ease symptoms in mice, study finds

    NEW YORK (AP) — Scientists eased symptoms of muscular dystrophy in mice by injecting modified stem cells from human patients, a preliminary result that raises hopes for treating patients with tissue from their own bodies.
    The mice showed stronger muscles and ran longer on a treadmill than diseased mice that weren’t treated.
    Other experimental treatments for muscular dystrophy have also produced encouraging results in lab animals. Last year, for example, scientists reported improvements in golden retrievers that had received stem cells from other dogs.
    The new study involved not only using stem cells, but also modifying those cells to affect how they read their DNA.
    The paper focused on Duchenne muscular dystrophy, a muscle-wasting genetic disorder appearing in boys that occurs in about 1 in every 3,500 male births. It’s the most severe and most common childhood form of muscular dystrophy.
    Boys with Duchenne dystrophy have trouble walking as early as preschool, and nearly all of them lose their ability to walk between ages 7 and 12. Typically, they die in their 20s because of weakness in their heart and lung muscles. There is no known cure.
    The idea of treating people with their own cells is attractive because their bodies would not be expected to reject the cells as foreign. So they wouldn’t have to take drugs to prevent rejection.
    The new study used stem cells taken from the muscle of Duchenne patients. These ‘‘adult’’ cells differ from embryonic stem cells, which are controversial because scientists must destroy embryos to harvest them.
    The work is published in the December issue of Cell Stem Cell by scientists from the University of Milan in Italy, and elsewhere. It used mice that had a version of Duchenne and whose immune systems don’t reject foreign tissue.
    Duchenne is caused by a mutated gene that prevents cells from producing a crucial protein. So just putting stem cells from patients with the faulty gene into the mice wouldn’t have done any good. Instead, researchers treated the cells to make them ignore the mutation. As a result, they produced a shortened but functioning version of the protein.
    This approach, called exon-skipping, is now being studied in early human experiments that seek to deliver the treatment within a Duchenne patient’s body.
    In the mouse study, the cells were treated outside the body. Scientists injected the treated cells into the bloodstreams of six mice. The cells settled near muscle damaged by the disease, and researchers later found the human protein in some mouse muscle fibers.
    Lab tests showed that leg muscles removed from the treated mice were stronger than those from untreated mice, although they remained weaker than normal. A treadmill study of four mice found that the treatment prolonged running time before exhaustion, but again not to the level of healthy mice.
    The work is ‘‘a nice demonstration of a lot of cutting-edge techniques used together and effectively,’’ said Sharon Hesterlee of the Muscular Dystrophy Association, which was not involved with the study.
    Scientists now must improve the technique and test the approach in larger animals, she said.

Interested in viewing premium content?

A subscription is required before viewing this article and other premium content.

Already a registered member and have a subscription?

If you have already purchased a subscription, please log in to view the full article.

Are you registered, but do not have a subscription?

If you are a registed user and would like to purchase a subscription, log in to view a list of available subscriptions.

Interested in becoming a registered member and purchasing a subscription?

Join our community today by registering for a FREE account. Once you have registered for a FREE account, click SUBSCRIBE NOW to purchase access to premium content.

Membership Benefits

  • Instant access to creating Blogs, Photo Albums, and Event listings.
  • Email alerts with the latest news.
  • Access to commenting on articles.

Please wait ...